Newamsterdam Pharma Stock Cash And Equivalents

NAMS Stock

20.20 0.08 0.40%

NewAmsterdam Pharma fundamentals help investors to digest information that contributes to NewAmsterdam Pharma's financial success or failures. It also enables traders to predict the movement of NewAmsterdam Stock. The fundamental analysis module provides a way to measure NewAmsterdam Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NewAmsterdam Pharma stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

NewAmsterdam Pharma Company Cash And Equivalents Analysis

NewAmsterdam Pharma's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Cash

Bank Deposits

+

Liquidities

More About Cash And Equivalents | All Equity Analysis

NewAmsterdam Cash And Equivalents Driver Correlations

Understanding the fundamental principles of building solid financial models for NewAmsterdam Pharma is extremely important. It helps to project a fair market value of NewAmsterdam Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since NewAmsterdam Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NewAmsterdam Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NewAmsterdam Pharma's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Good Will	Intangible Assets
Total Assets		1.0	0.82	-0.98	-0.75	0.89	0.93	1.0	-0.48	1.0	0.77	1.0	-0.83	0.77	0.82	0.99	-0.94	-0.48	-0.55
Total Stockholder Equity	1.0		0.82	-0.98	-0.74	0.88	0.91	1.0	-0.46	0.99	0.79	1.0	-0.83	0.79	0.82	0.99	-0.93	-0.46	-0.52
Net Tangible Assets	0.82	0.82		-0.88	-0.85	0.94	0.78	0.81	-0.68	0.84	0.46	0.84	-1.0	0.46	0.95	0.8	-0.85	-0.68	-0.72
Net Debt	-0.98	-0.98	-0.88		0.85	-0.93	-0.94	-0.98	0.63	-0.99	-0.66	-0.99	0.87	-0.66	-0.83	-0.99	0.98	0.63	0.68
Retained Earnings	-0.75	-0.74	-0.85	0.85		-0.9	-0.88	-0.73	0.9	-0.8	-0.17	-0.78	0.8	-0.17	-0.73	-0.77	0.92	0.9	0.96
Accounts Payable	0.89	0.88	0.94	-0.93	-0.9		0.93	0.87	-0.63	0.92	0.47	0.92	-0.93	0.47	0.94	0.85	-0.94	-0.63	-0.76
Total Liab	0.93	0.91	0.78	-0.94	-0.88	0.93		0.91	-0.61	0.95	0.5	0.94	-0.76	0.5	0.78	0.91	-0.98	-0.61	-0.75
Net Invested Capital	1.0	1.0	0.81	-0.98	-0.73	0.87	0.91		-0.46	0.99	0.79	1.0	-0.81	0.79	0.81	0.99	-0.93	-0.46	-0.52
Short Long Term Debt	-0.48	-0.46	-0.68	0.63	0.9	-0.63	-0.61	-0.46		-0.52	0.1	-0.51	0.61	0.1	-0.44	-0.55	0.71	1.0	0.94
Total Current Assets	1.0	0.99	0.84	-0.99	-0.8	0.92	0.95	0.99	-0.52		0.72	1.0	-0.84	0.72	0.84	0.98	-0.96	-0.52	-0.6
Capital Stock	0.77	0.79	0.46	-0.66	-0.17	0.47	0.5	0.79	0.1	0.72		0.74	-0.52	1.0	0.55	0.75	-0.52	0.1	0.1
Net Working Capital	1.0	1.0	0.84	-0.99	-0.78	0.92	0.94	1.0	-0.51	1.0	0.74		-0.84	0.74	0.84	0.98	-0.96	-0.51	-0.58
Short Term Debt	-0.83	-0.83	-1.0	0.87	0.8	-0.93	-0.76	-0.81	0.61	-0.84	-0.52	-0.84		-0.52	-0.96	-0.79	0.83	0.61	0.65
Common Stock	0.77	0.79	0.46	-0.66	-0.17	0.47	0.5	0.79	0.1	0.72	1.0	0.74	-0.52		0.55	0.75	-0.52	0.1	0.1
Property Plant Equipment	0.82	0.82	0.95	-0.83	-0.73	0.94	0.78	0.81	-0.44	0.84	0.55	0.84	-0.96	0.55		0.75	-0.79	-0.44	-0.56
Current Deferred Revenue	0.99	0.99	0.8	-0.99	-0.77	0.85	0.91	0.99	-0.55	0.98	0.75	0.98	-0.79	0.75	0.75		-0.95	-0.55	-0.58
Net Receivables	-0.94	-0.93	-0.85	0.98	0.92	-0.94	-0.98	-0.93	0.71	-0.96	-0.52	-0.96	0.83	-0.52	-0.79	-0.95		0.71	0.79
Good Will	-0.48	-0.46	-0.68	0.63	0.9	-0.63	-0.61	-0.46	1.0	-0.52	0.1	-0.51	0.61	0.1	-0.44	-0.55	0.71		0.94
Intangible Assets	-0.55	-0.52	-0.72	0.68	0.96	-0.76	-0.75	-0.52	0.94	-0.6	0.1	-0.58	0.65	0.1	-0.56	-0.58	0.79	0.94

Click cells to compare fundamentals

Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

Competition

Predict NewAmsterdam Pharma

In accordance with the recently published financial statements, NewAmsterdam Pharma has 0.0 in Cash And Equivalents. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 100.0% higher than that of the company.

NewAmsterdam Cash And Equivalents Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NewAmsterdam Pharma's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NewAmsterdam Pharma could also be used in its relative valuation, which is a method of valuing NewAmsterdam Pharma by comparing valuation metrics of similar companies.

NewAmsterdam Pharma is currently under evaluation in cash and equivalents category among its peers.

NewAmsterdam Pharma ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, NewAmsterdam Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to NewAmsterdam Pharma's managers, analysts, and investors.

Environmental

Governance

Social

NewAmsterdam Fundamentals

	Return On Equity	-0.47
	Return On Asset	-0.29
	Operating Margin	(0.86) %
	Current Valuation	1.44 B
	Shares Outstanding	92.39 M
	Shares Owned By Insiders	0.25 %
	Shares Owned By Institutions	84.04 %
	Number Of Shares Shorted	718.04 K
	Price To Book	4.93 X
	Price To Sales	55.55 X
	Revenue	12.76 M
	EBITDA	(165.69 M)
	Net Income	(160.27 M)
	Total Debt	60 K
	Book Value Per Share	4.11 X
	Cash Flow From Operations	(141.22 M)
	Short Ratio	2.92 X
	Earnings Per Share	(2.21) X
	Target Price	37.0
	Number Of Employees	62
	Beta	-0.001
	Market Capitalization	2.29 B
	Total Asset	347.1 M
	Retained Earnings	(316.97 M)
	Working Capital	296.89 M
	Net Asset	347.1 M

About NewAmsterdam Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze NewAmsterdam Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NewAmsterdam Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NewAmsterdam Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC